Free Newsletter
Merck expands Januvia label
In a sort of good news/bad news move, the FDA is allowing Merck to expand marketing of the diabetes drug Januvia--but it's also expanding the warnings on Januvia's label.
Now, Merck can sell the drug for use in combo with other diabetes meds, rather than as a supplement to diet and exercise alone. The new label will highlight warnings of hypersensitivity reactions, including the rare-but-deadly Stevens-Johnson syndrome.
- take a look at Merck's release
- read the report from the Houston Chronicle
Related Articles:
ADA meeting sees new data on diabetes drugs. Report
FDA expected to approve Januvia soon. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





